MYK-224 for Healthy Subjects

Labcorp Clinical Research Unit - Madison, Madison, WI
Healthy SubjectsMYK-224 - Drug

Study Summary

This trial looks into the effects of a drug on healthy men over 3 weeks.

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

3 Primary · 6 Secondary · Reporting Duration: Up to 45 days

Up to 45 days
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))
Maximum observed concentration (Cmax)
Metabolite profiling of BMS-986435 in plasma, urine, and feces
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory abnormalities
Number of participants with electrocardiogram (ECG) abnormalities
Number of participants with physical examination abnormalities
Number of participants with vital sign abnormalities
Time to maximum observed concentration (Tmax)

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

7 Total Participants · 1 Treatment Group

Primary Treatment: MYK-224 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: MYK-224 · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 45 days

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,537 Previous Clinical Trials
4,019,328 Total Patients Enrolled

Eligibility Criteria

Age 18 - 55 · Male Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your body mass index (BMI) falls between 18 and 32 kg/m^2.

Frequently Asked Questions

Are there any remaining opportunities to join this research endeavor?

"According to the webpage, this medical trial is still recruiting patients since its initial posting on January 16th of 2023 and last update in March 17th of same year." - Anonymous Online Contributor

Unverified Answer

Does the trial accept applicants aged sixty or above?

"This trial specifically seeks patients aged 18 to 55. However, there are 54 clinical studies available for minors and 368 trials targeting seniors." - Anonymous Online Contributor

Unverified Answer

How many participants are being welcomed into the experiment?

"Affirmative. The information posted on attests to this medical study's actively recruitment process, which was kickstarted on January 16th 2023 and recently updated March 17th 2023. 8 patients need to be sourced from a single location for the trial to commence." - Anonymous Online Contributor

Unverified Answer

Has MYK-224 been granted clearance by the FDA?

"Our team at Power gave MYK-224 a score of 1 due to the fact that this Phase 1 trial has only limited evidence backing its safety and efficacy." - Anonymous Online Contributor

Unverified Answer

Am I eligible to be a participant in this research endeavor?

"This trial is open to 8 individuals aged 18-55 who are in good health. Furthermore, these participants must have a documented LVEF of at least 60%, BMI between 18 and 32 kg/m^2, be male as determined by the investigator and sponsor, and possess acoustic windows that allow for accurate assessment of LV systolic activity from TTEs." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.